Clinical Trial Update: Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 study assessing Lutetium-177-DGUL in combination with Pembrolizumab for metastatic castration-resistant prostate cancer; the trial status is NOT_YET_REC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177-DGUL
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Cellbion Co., Ltd. | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Status: NOT_YET_RECRUITING